[Metformin and kidneys].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): Smahelová A;Smahelová A
  • Source:
    Vnitrni lekarstvi [Vnitr Lek] 2008 May; Vol. 54 (5), pp. 535-40.
  • Publication Type:
    Journal Article; Review
  • Language:
    Czech
  • Additional Information
    • Transliterated Title:
      Metformin a ledviny.
    • Source:
      Publisher: Ambit Media Country of Publication: Czech Republic NLM ID: 0413602 Publication Model: Print Cited Medium: Print ISSN: 0042-773X (Print) Linking ISSN: 0042773X NLM ISO Abbreviation: Vnitr Lek Subsets: MEDLINE
    • Publication Information:
      Publication: 2010- : Brno : Ambit Media
      Original Publication: 1973-<1994> : Praha : Avicenum
    • Subject Terms:
    • Abstract:
      Metformin is currently recommended as the first-line drug for type 2 diabetic patients once the disease has been diagnosed. In addition to antihyperglycaemic effect, it has other effects which have a positive effect on cardiovascular risk. The greatest risk of metformin treatment is lactate acidosis, but its incidence is very low if the contraindications are observed. In spite of the fact that not all contraindications are observed in practice, the incidence of lactate acidosis demonstrably provoked by metformin does not grow. In spite of ongoing discussion on the subject, contraindications still include all states involving the risk of lactacidosis including renal insufficiency.
    • Number of References:
      15
    • Accession Number:
      0 (Hypoglycemic Agents)
      9100L32L2N (Metformin)
    • Publication Date:
      Date Created: 20080718 Date Completed: 20080909 Latest Revision: 20171116
    • Publication Date:
      20240628
    • Accession Number:
      18630642